CAS 4682-36-4|orphenadrine citrate

Introduction：Basic information about CAS 4682-36-4|orphenadrine citrate, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.

Table of Contents

1. Names
2. orphenadrine citrate BiologicalActivity
3. Chemical & Physical Properties
4. Safety Information
5. Articles28
6. Synonyms

Common Name	orphenadrine citrate
CAS Number	4682-36-4	Molecular Weight	461.50500
Density	1.014 g/cm3	Boiling Point	363ºC at 760 mmHg
Molecular Formula	C₂₄H₃₁NO₈	Melting Point	132-134ºC
MSDS	ChineseUSA	Flash Point	107.1ºC
Symbol	GHS07, GHS08	Signal Word	Warning

Names

Name	orphenadrine citrate
Synonym	More Synonyms

orphenadrine citrate BiologicalActivity

Description	Orphenadrine citrate is a NMDA receptor antagonist with Ki of 6.0 +/- 0.7 μM, HERG potassium channel blocker.Target: NMDA ReceptorOrphenadrine has been used as an antiparkinsonian, antispastic and analgesic drug. Orphenadrine inhibits [3H]MK-801 binding to the phencyclidine (PCP) binding site of the N-methyl-D-aspartate (NMDA)-receptor in homogenates of postmortem human frontal cortex with a Ki-value of 6.0 +/- 0.7 microM. The NMDA receptor antagonistic effects of orphenadrine were assessed using concentration- and patch-clamp techniques on cultured superior colliculus neurones. Orphenadrine blocked open NMDA receptor channels with fast kinetics and in a strongly voltage-dependent manner. The IC50-value against steady state currents at -70 mV was 16.2 +/- 1.6 microM (n = 6). Orphenadrine exhibited relatively fast, concentration-dependent open channel blocking kinetics (Kon 0.013 +/- 0.002 10(6) M-1S-1) whereas the offset rate was concentration-independent (Koff 0.230 +/- 0.004 S-1) [1]. Orphenadrine competitively inhibited [3H]nisoxetine binding in rat vas deferens membranes (Ki = 1.05+/-0.20 microM). It can be concluded that orphenadrine, at low micromolar concentrations, interacts with the noradrenaline reuptake system inhibiting its functionality and thus potentiating the effect of noradrenaline [2].
Related Catalog	Signaling Pathways >>Membrane Transporter/Ion Channel >>iGluRSignaling Pathways >>Neuronal Signaling >>iGluRResearch Areas >>Neurological Disease
References	[1]. Kornhuber, J., et al., Orphenadrine is an uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist: binding and patch clamp studies. J Neural Transm Gen Sect, 1995. 102(3): p. 237-46. [2]. Pubill, D., et al., Assessment of the adrenergic effects of orphenadrine in rat vas deferens. J Pharm Pharmacol, 1999. 51(3): p. 307-12.

Description

Orphenadrine citrate is a NMDA receptor antagonist with Ki of 6.0 +/- 0.7 μM, HERG potassium channel blocker.Target: NMDA ReceptorOrphenadrine has been used as an antiparkinsonian, antispastic and analgesic drug. Orphenadrine inhibits [3H]MK-801 binding to the phencyclidine (PCP) binding site of the N-methyl-D-aspartate (NMDA)-receptor in homogenates of postmortem human frontal cortex with a Ki-value of 6.0 +/- 0.7 microM. The NMDA receptor antagonistic effects of orphenadrine were assessed using concentration- and patch-clamp techniques on cultured superior colliculus neurones. Orphenadrine blocked open NMDA receptor channels with fast kinetics and in a strongly voltage-dependent manner. The IC50-value against steady state currents at -70 mV was 16.2 +/- 1.6 microM (n = 6). Orphenadrine exhibited relatively fast, concentration-dependent open channel blocking kinetics (Kon 0.013 +/- 0.002 10(6) M-1S-1) whereas the offset rate was concentration-independent (Koff 0.230 +/- 0.004 S-1) [1]. Orphenadrine competitively inhibited [3H]nisoxetine binding in rat vas deferens membranes (Ki = 1.05+/-0.20 microM). It can be concluded that orphenadrine, at low micromolar concentrations, interacts with the noradrenaline reuptake system inhibiting its functionality and thus potentiating the effect of noradrenaline [2].

Related Catalog

Signaling Pathways >>Membrane Transporter/Ion Channel >>iGluRSignaling Pathways >>Neuronal Signaling >>iGluRResearch Areas >>Neurological Disease

References

[1]. Kornhuber, J., et al., Orphenadrine is an uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist: binding and patch clamp studies. J Neural Transm Gen Sect, 1995. 102(3): p. 237-46.

[2]. Pubill, D., et al., Assessment of the adrenergic effects of orphenadrine in rat vas deferens. J Pharm Pharmacol, 1999. 51(3): p. 307-12.

Chemical & Physical Properties

Density	1.014 g/cm3
Boiling Point	363ºC at 760 mmHg
Melting Point	132-134ºC
Molecular Formula	C₂₄H₃₁NO₈
Molecular Weight	461.50500
Flash Point	107.1ºC
Exact Mass	461.20500
PSA	133.60000
LogP	2.75980
InChIKey	MMMNTDFSPSQXJP-UHFFFAOYSA-N
SMILES	Cc1ccccc1C(OCCN(C)C)c1ccccc1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Storage condition	2-8°C

Safety Information

Symbol	GHS07, GHS08
Signal Word	Warning
Hazard Statements	H302-H351
Precautionary Statements	P281
Hazard Codes	Xi:Irritant;
Risk Phrases	R22;R40
Safety Phrases	S22-S36
RIDADR	UN 3249
WGK Germany	3
Packaging Group	III
Hazard Class	6.1(b)

Articles28

Preclinical evaluation of marketed sodium channel blockers in a rat model of myotonia discloses promising antimyotonic drugs.

Exp. Neurol. 255 , 96-102, (2014)

Although the sodium channel blocker mexiletine is considered the first-line drug in myotonia, some patients experiment adverse effects, while others do not gain any benefit. Other antimyotonic drugs a...

Spectrophotometric determination of tizanidine and orphenadrine via ion pair complex formation using eosin Y.

Chem. Cent. J. 5 , 60, (2011)

A simple, sensitive and rapid spectrophotometric method was developed and validated for the determination of two skeletal muscle relaxants namely, tizanidine hydrochloride (I) and orphenadrine citrate...

Reduction of tinnitus severity by the centrally acting muscle relaxant cyclobenzaprine: an open-label pilot study.

Audiol. Neurootol. 17(3) , 179-88, (2012)

Tinnitus, the phantom perception of sounds, is a highly prevalent disorder. Although a wide variety of drugs have been investigated off label for the treatment of tinnitus, there is no approved pharma...

Synonyms

Orphenadrine Citrate

Orphenadrine Citrate Salt

MFCD00079197

EINECS 225-137-5

Recommended......